Influenza Clinical Trial
Official title:
A Phase 2a Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) in Healthy Adults
Verified date | July 2013 |
Source | Novavax |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
A Phase 2a Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and
Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine (recombinant) in
Healthy Adults.
Study Objectives:
Primary:
- To assess the tolerability and safety of Influenza VLP Vaccine
- To assess the immunogenicity of Influenza VLP Vaccine as measured by hemagglutination
inhibition (HAI) antibody titers to each of the three component viral strains
Secondary:
- To evaluate the cross-strain immunogenicity of Influenza VLP Vaccine as measured by
hemagglutination inhibition (HAI) antibody titers against drifted strains
- To quantify antibody against neuraminidase and hemagglutinin following administration
of Influenza VLP Vaccine
- To assess cell-mediated immune (CMI) responses to Influenza VLP Vaccine as quantified
by interferon-gamma (IFNg) and Granzyme-B produced by peripheral blood mononuclear
cells (PBMCs).
Status | Completed |
Enrollment | 317 |
Est. completion date | March 2009 |
Est. primary completion date | March 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 49 Years |
Eligibility |
Inclusion Criteria: 1. Healthy male or female 18 to 49 years of age at the time of the vaccination. 2. Informed consent must be obtained from the subject prior to beginning any study specific procedures indicating that they understand the purpose of this study and are willing to adhere to the procedures described in this protocol. 3. Available by telephone. 4. Free of obvious health problems or chronic illnesses (i.e., recent exacerbation or acute episode of chronic illness in the last 3 months) as established by medical history, review of systems and clinical examination before entering the study. This includes any mental condition that would interfere with subject self-assessment. Subjects with pre-existing stable disease, defined as no significant disease diagnosed in the month prior to study vaccine receipt and disease not requiring significant change in therapy or hospitalization for worsening disease 3 months before receipt of study vaccine are eligible. 5. If subject is of childbearing potential, she must be abstinent or have used adequate contraceptive precautions (e.g., intrauterine contraceptive device; oral contraceptives or other equivalent hormonal contraception) for 3 months prior to vaccination. She must also have a negative pregnancy test at study entry and must agree to continue such precautions for three months after vaccination. Exclusion Criteria: 1. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the administration of the study vaccine, or planned use during the study period. 2. Has received any other licensed vaccines within 4 weeks prior to enrollment in this study or expected receipt of any vaccination before the final immune response blood collection. 3. Has received any influenza vaccine within the prior 6 month period. 4. Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the administration of the study vaccine. The use of inhaled and nasal steroids will be permitted. 5. Any medically diagnosed or suspected immunodeficient condition based on medical history and physical examination. 6. Administration of immunoglobulins and/or any blood products within the three months preceding the administration of the study vaccine or during the study. 7. Acute disease at the time of enrollment. Acute disease is defined as the presence of a moderate or severe illness with or without fever = 100.5º F. 8. Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. 9. Major congenital defects or serious chronic illness. 10. History of any neurological disorders or seizures, with the exception of febrile seizures during childhood. 11. Pregnant or lactating female. 12. Females planning to become pregnant or planning to discontinue contraceptive precautions within 60 days of enrollment in this study. 13. Any condition that in the opinion of the investigator would interfere with evaluation of the vaccine or interpretation of study results. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | Benchmark Research | Austin | Texas |
United States | The Center for Pharmacuetical Research | Kansas City | Missouri |
United States | University Clinical Research | Pembroke Pines | Florida |
United States | Omega Medical Research | Warwick | Rhode Island |
Lead Sponsor | Collaborator |
---|---|
Novavax |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess the tolerability and safety of Influenza VLP Vaccine | 6 Months | Yes | |
Primary | To assess the immunogenicity of Influenza VLP Vaccine as measured by hemagglutination inhibition (HAI) antibody titers to each of the component viral strains | Day 22 | No | |
Secondary | To evaluate cross-strain immunogenicity as measured by HAI titers against drifted strains | Day 22 | No | |
Secondary | To quantify antibody responses against neuraminidase and hemagglutinin | Day 22 | No | |
Secondary | To assess cell-mediated immune (CMI) responses to Influenza VLP Vaccine | Day 11 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |